Gain Therapeutics

Gain Therapeutics (NASDAQ: GANX) is a preclinical biotechnology company focused on developing new medicines for protein misfolding diseases. Gain’s supercomputer-driven, target-based drug discovery platform, “SEE-Tx,” is a novel approach that uses structural and computational biology to discover previously unidentified allosteric binding sites with high potential for druggability. These sites can be targeted with small molecules for therapeutic benefit to correct enzyme misfolding, thereby restoring function, eliminating toxic substrate, and addressing the underlying cause of disease.